AbbVie Inc.

As of June 30, 2026, AbbVie, Inc. carries a market capitalization of 304.76B, placing it among publicly traded companies globally. Its enterprise value stands at 356.70B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

AbbVie, Inc.'s next confirmed earnings release is scheduled for October 30, 2026.

As of June 30, 2026, AbbVie, Inc. has 1.77B shares outstanding.

As of June 30, 2026, AbbVie, Inc. trades at a trailing price-to-earnings ratio of 59.79. The price-to-sales ratio is 5.86, and the price-to-book ratio stands at -63.56.

As of June 30, 2026, AbbVie, Inc. trades at an EV/EBITDA multiple of 17.85 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 6.86 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 26.17 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. AbbVie, Inc. trades at an EV/FCF ratio of 21.72, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 356.70B versus a market cap of 304.76B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, AbbVie, Inc. maintains a current ratio of 0.81, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -1,202.82, indicating conservative leverage, while an interest coverage ratio of 8.48 demonstrates adequate ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on invested capital (ROIC) comes in at 18.11 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 4.63, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 12.45, useful for judging operating efficiency across full business cycles. The company generates approximately 920,583.05 in revenue per employee across its workforce of 56,500.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.64 indicates how many times AbbVie, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, AbbVie, Inc. recorded 1.93B in income tax expense. That works out to an effective tax rate of 27.39, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 7.03B, leaving 5.10B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 13, 2026, AbbVie, Inc.'s stock has gained approximately 141.85% over the past 52 weeks.

Over the twelve months ended June 30, 2026, AbbVie, Inc. generated 52.01B in revenue and converted that into 5.10B in net income, yielding earnings per share of 2.88. EBITDA reached 19.98B, while operating income came in at 17.65B.

As of June 30, 2026, AbbVie, Inc. holds 5.31B in cash and equivalents against 57.21B in total debt, resulting in a net debt position of 51.91B. Total book value stands at -4.79B, with working capital of -6.44B providing operational flexibility.

AbbVie, Inc. produced 15.76B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.05B in capital expenditures, free cash flow totaled 14.71B - equivalent to 8.32 per share.

Over the twelve months ended June 30, 2026, AbbVie, Inc. posted a gross margin of 71.48, reflecting its pricing power and cost economics. The operating margin of 33.94 and net profit margin of 9.80 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, AbbVie, Inc. paid dividends of 5.48 per share. The dividend payout ratio of 189.47 exceeds 100%, meaning the company is distributing more than it earns and funding the dividend from cash reserves, asset sales, or borrowing, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 4.81, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 3.42, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to AbbVie, Inc. shareholders.

As of June 30, 2026, AbbVie, Inc. has an Altman Z-Score of 3.64, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.